The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates.

COVID-19 vaccine GS linker SARS-CoV-2 Th1 immune responses chimeric adenovirus-vectored vaccine neutralizing activity variants

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
30 Apr 2022
Historique:
received: 06 04 2022
revised: 25 04 2022
accepted: 27 04 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

Several COVID-19 platforms have been licensed across the world thus far, but vaccine platform research that can lead to effective antigen delivery is still ongoing. Here, we constructed AdCLD-CoV19 that could modulate humoral immunity by harboring SARS-CoV-2 antigens onto a chimeric adenovirus 5/35 platform that was effective in cellular immunity. By replacing the S1/S2 furin cleavage sequence of the SARS-CoV-2 Spike (S) protein mounted on AdCLD-CoV19 with the linker sequence, high antigen expression was confirmed in various cell lines. The high levels of antigen expression contributed to antigen-specific antibody activity in mice and non-human primates (NHPs) with a single vaccination of AdCLD-CoV19. Furthermore, the adenovirus-induced T

Identifiants

pubmed: 35632468
pii: vaccines10050712
doi: 10.3390/vaccines10050712
pmc: PMC9147121
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Research Foundation of Korea
ID : 2020M3A9I2107463
Organisme : ministry of science and ICT of korea
ID : PRM1752011
Organisme : Korea Research Institute of Bioscience and Biotechnology
ID : KGM4572121

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Chem Sci. 2019 Oct 7;10(44):10428-10435
pubmed: 32110335
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Gene Ther. 2004 Oct;11 Suppl 1:S10-7
pubmed: 15454952
Science. 2021 Dec 10;374(6573):1353-1360
pubmed: 34698504
BMJ. 2021 Feb 5;372:n359
pubmed: 33547053
ACS Cent Sci. 2021 Apr 28;7(4):594-602
pubmed: 34056089
J Clin Med. 2020 Feb 20;9(2):
pubmed: 32093211
Nat Microbiol. 2021 Jul;6(7):821-823
pubmed: 34108654
Gene Ther. 2014 Jan;21(1):106-14
pubmed: 24225639
Blood. 2007 Sep 15;110(6):1916-23
pubmed: 17510320
Mol Biosyst. 2017 Feb 28;13(3):598-606
pubmed: 28181620
J Chem Inf Model. 2022 Jan 24;62(2):412-422
pubmed: 34989238
FEBS Lett. 2019 Dec;593(24):3461-3483
pubmed: 31769012
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Eur Respir J. 2020 May 27;55(5):
pubmed: 32312864
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Nature. 2020 Aug;584(7821):353-363
pubmed: 32659783
Mol Ther. 2006 Apr;13(4):756-65
pubmed: 16461009
JAMA. 2021 Apr 20;325(15):1535-1544
pubmed: 33704352
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Adv Drug Deliv Rev. 2013 Oct;65(10):1357-69
pubmed: 23026637
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Cell. 2019 Apr 18;177(3):524-540
pubmed: 31002794
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Mol Ther. 2020 Mar 4;28(3):709-722
pubmed: 31968213
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Nat Commun. 2020 Aug 14;11(1):4081
pubmed: 32796842
NPJ Vaccines. 2020 Sep 28;5:91
pubmed: 33083026
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
Signal Transduct Target Ther. 2020 Oct 13;5(1):237
pubmed: 33051445
Lancet Infect Dis. 2021 Aug;21(8):1070
pubmed: 34022142
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Front Immunol. 2020 Sep 28;11:581807
pubmed: 33117391
J Infect Dis. 2020 Oct 13;222(10):1596-1600
pubmed: 32745172
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
Signal Transduct Target Ther. 2020 Jun 12;5(1):92
pubmed: 32532959
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279

Auteurs

Seung-Phil Shin (SP)

Cellid Co., Ltd., Seoul 08826, Korea.

Kwang-Soo Shin (KS)

Cellid Co., Ltd., Seoul 08826, Korea.

Jeong-Mi Lee (JM)

Cellid Co., Ltd., Seoul 08826, Korea.

In-Kyung Jung (IK)

Cellid Co., Ltd., Seoul 08826, Korea.

Jimo Koo (J)

Cellid Co., Ltd., Seoul 08826, Korea.

Seung-Woo Lee (SW)

Cellid Co., Ltd., Seoul 08826, Korea.

Seowoo Park (S)

Cellid Co., Ltd., Seoul 08826, Korea.

Jieun Shin (J)

Cellid Co., Ltd., Seoul 08826, Korea.

Myunghwan Park (M)

Cellid Co., Ltd., Seoul 08826, Korea.

Bongju Park (B)

Cellid Co., Ltd., Seoul 08826, Korea.

Hanseul Oh (H)

National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Korea.

Bon-Sang Koo (BS)

National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Korea.

Jungjoo Hong (J)

National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Korea.

Choong-Min Ryu (CM)

Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea.

Jae-Ouk Kim (JO)

Science Unit, International Vaccine Institute, Seoul 08826, Korea.

Taegwon Oh (T)

Cellid Co., Ltd., Seoul 08826, Korea.

Chang-Yuil Kang (CY)

Cellid Co., Ltd., Seoul 08826, Korea.
Laboratory of Immunology, Research Institute of Pharmaceutical Science, College of Pharmacy, Seoul National University, Seoul 08826, Korea.

Classifications MeSH